COLUMVI (glofitamab-gxbm) ROCHE Indications: COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from foll...
Being spotted in multiple cancer types, lymph node (LN) metastasis literally is the symbol of dreadful patient outcomes, characterizing poor prognosis and shorter survival. Recent research has highlighted sentinel LNs as the gateway for haematogenou...
Renal cell carcinomas (RCCs) are the most common type of kidney cancer in adults and is prevalent in adult male aged between 60 and 70. Notably, clear cell RCC (ccRCC) is the most abundant subtype of RCC with the worse disease-specific survival as i...
Exkivity® ( mobocertinib ) 1-3 Takeda Mobocertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that selectively inhibits and irreversibly binds to EGFR exon 20 insertion mutations at lower concentrations than Wild type (...
Pancreatic ductal adenocarcinoma (PDA) is called a silent killer, as it is often discovered late and has a high mortality rate. Its treatment-resistant and aggressive nature can be attributed to the tumour microenvironment, low vascularity, and meta...
Existing Knowledge on Colorectal Cancer Colorectal cancer (CRC) is the third most common type of cancer and second most common cause of cancer-related deaths globally 1 . There were over 1.9 million new cases of CRC globally in 2020 with medium to h...
Chronic lymphocytic leukaemia (CLL) is a chronic lymphoproliferative disorder characterised by proliferation of monoclonal mature B-cells in peripheral blood, bone marrow, and secondary lymphoid tissues, such as spleen and lymph nodes 1 . The incide...
The management of relapsed and refractory multiple myeloma (RRMM) continues to be challenging though new therapeutics for the disease have been emerging in recent decades. Essentially, while decreased survival was observed in each extra line of ther...
Currently Available Therapeutic Options for MM MM is currently one of the most prevalent haematological malignancies, which mainly affects individuals aged above 65 2 , a relatively vulnerable group of patients owing to comorbidities and immunosenes...
The Multitude of Activities of IMiDs Because of the established benefits, IMiDs are recommended as induction therapy for both transplant eligible and ineligible patients, in the post-transplant maintenance setting, and for relapsed/refractory diseas...
Background Information The patient of the current case was a 64-year-old male with documented ischemic heart disease and received 3 times of percutaneous coronary intervention (PCI), respectively in 2004, 2005 and 2013. In 2015, the patient complain...
